
Conference Coverage
about 13 hours ago
Early Antibiotic Stop in Neutropenic Fever Did Not Raise Severe Eventsabout 16 hours ago
Asuptegravir Lowers HIV-1 RNA up to 2.36 Logs in Early Monotherapyabout 19 hours ago
Fecal Microbiota Spores Cut Early Hospitalizations in Recurrent C diffabout 21 hours ago
Ensitrelvir PEP Eases Symptom Severity in COVID-19 Breakthrough CasesLatest Content

Early Antibiotic Stop in Neutropenic Fever Did Not Raise Severe Events

Asuptegravir Lowers HIV-1 RNA up to 2.36 Logs in Early Monotherapy

Fecal Microbiota Spores Cut Early Hospitalizations in Recurrent C diff

CDC Tracking 5 Active Food-Borne Outbreaks Tied to Oysters, Cheese, Sprouts

Ensitrelvir PEP Eases Symptom Severity in COVID-19 Breakthrough Cases

Shorts










Videos
Contagion Digital Edition









All News

Day 42 all-cause mortality was 23.8% with oral olorofim vs 24.3% with AmBisome plus standard of care in invasive aspergillosis unsuited to azole therapy.

MBL producers rose from 20.4% to 48.6% of US carbapenem-resistant Enterobacterales from 2021 to 2025, while aztreonam-avibactam stayed active against 97.7% of them.

Switching to once-daily bictegravir/lenacapavir kept adverse event rates similar to comparators and metabolic markers stable across comorbidity groups in ARTISTRY-1 and -2.

The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.

Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.

Isavuconazole had a lower liver adverse event signal than voriconazole and posaconazole, while olorofim, manogepix, and rezafungin held activity against resistant molds.

Data being presented at IDWeek 2026 show zoliflodacin maintains high gonorrhea cure rates in patients co-infected with chlamydia. David Altarac, MD, discusses the therapy and the study being presented at the conference.

In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.

Oral pritelivir improved lesion healing and cut hospitalizations from 76% to 29.4% vs investigator's choice therapy in immunocompromised patients with refractory HSV.

Investigational cefiderocol-xeruborbactam inhibited 98.5% of carbapenem-nonsusceptible Acinetobacter and nearly all Enterobacterales in global surveillance data.

Oral zelicapavir cut time to complete RSV symptom resolution by up to 1 week in high-risk adults, but it did not meet its primary end point in a phase 2 trial.

The FDA approved bepirovirsen (Hibsago; GSK) with nucleos(t)ide analogue therapy for chronic hepatitis B, based on B-Well 1 and 2 functional cure rates of 19% vs 0% with placebo.

In the phase 2 RePreve trial, Lumen Bioscience’s investigational oral biologic LMN-201 plus standard antibiotics achieved global cure in 83.3% of patients with C difficile infection vs 36.4% with placebo, and cut recurrence sixfold (9.1% vs 55.6%) with no drug-related serious adverse events.

The first animal model of neonatal sepsis to evaluate protection by maternal vaccination evidences transfer of immunity against virulent, often antibiotic-resistant Klebseilla pneumoniae.

The CHMP adopted a positive opinion on an extension of indication for AstraZeneca's H5N1 pandemic influenza vaccine at its October meeting.




















































































































































































